These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 32690996)
41. Effect of EARLY administration of DEXamethasone in patients with COVID-19 pneumonia without acute hypoxemic respiratory failure and risk of development of acute respiratory distress syndrome (EARLY-DEX COVID-19): study protocol for a randomized controlled trial. Franco-Moreno A; Acedo-Gutiérrez MS; Martín NL; Hernández-Blanco C; Rodríguez-Olleros C; Ibáñez-Estéllez F; Suárez-Simón A; Balado-Rico M; Romero-Paternina AR; Alonso-Menchén D; Escolano-Fernández B; Piniella-Ruiz E; Alonso-Monge E; Notario-Leo H; Bibiano-Guillén C; Peña-Lillo G; Antiqueira-Pérez A; Romero-Pareja R; Cabello-Clotet N; Estrada-Pérez V; Troya-García J; de Carranza-López M; Escobar-Rodríguez I; Vallejo-Maroto N; Torres-Macho J Trials; 2022 Sep; 23(1):784. PubMed ID: 36109825 [TBL] [Abstract][Full Text] [Related]
42. Lung microbiome and coronavirus disease 2019 (COVID-19): Possible link and implications. Khatiwada S; Subedi A Hum Microb J; 2020 Aug; 17():100073. PubMed ID: 32835135 [TBL] [Abstract][Full Text] [Related]
43. The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect. Can A; Coskun H Stem Cells Transl Med; 2020 Nov; 9(11):1287-1302. PubMed ID: 32779878 [TBL] [Abstract][Full Text] [Related]
44. Coronavirus disease 2019 (COVID-19) update: From metabolic reprogramming to immunometabolism. Rudiansyah M; Jasim SA; Mohammad Pour ZG; Athar SS; Jeda AS; Doewes RI; Jalil AT; Bokov DO; Mustafa YF; Noroozbeygi M; Karampoor S; Mirzaei R J Med Virol; 2022 Oct; 94(10):4611-4627. PubMed ID: 35689351 [TBL] [Abstract][Full Text] [Related]
45. Does Methylene Blue Satisfy an Option in COVID-19 ARDS. Yella SHT; Yella SST; Sasanka KSBSK; Thangaraju P Infect Disord Drug Targets; 2022; 22(6):e170322202339. PubMed ID: 35301956 [TBL] [Abstract][Full Text] [Related]
46. Could Oral Phosphodiesterase 5 Inhibitors Have a Potential Adjuvant Role in Combating COVID-19 Infection? Mostafa T Sex Med Rev; 2021 Jan; 9(1):15-22. PubMed ID: 33077403 [TBL] [Abstract][Full Text] [Related]
47. Severity of COVID-19 infection in primary Sjögren's syndrome and the emerging evidence of COVID-19-induced xerostomia. Chowdhury F; Grigoriadou S; Bombardieri M Clin Exp Rheumatol; 2021; 39 Suppl 133(6):215-222. PubMed ID: 34919045 [TBL] [Abstract][Full Text] [Related]
48. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial. Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777 [TBL] [Abstract][Full Text] [Related]
49. Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration. Chen R; Lan Z; Ye J; Pang L; Liu Y; Wu W; Qin X; Guo Y; Zhang P Front Immunol; 2021; 12():589095. PubMed ID: 33995341 [TBL] [Abstract][Full Text] [Related]
50. Pathomechanisms Underlying Hypoxemia in Two COVID-19-Associated Acute Respiratory Distress Syndrome Phenotypes: Insights From Thrombosis and Hemostasis. Gando S; Wada T Shock; 2022 Jan; 57(1):1-6. PubMed ID: 34172612 [TBL] [Abstract][Full Text] [Related]
51. Pneumomediastinum in COVID-19 Patients with Acute Respiratory Distress Syndrome. Pokhrel B; Adhikari G; Pangeni R; Regmi PR; Baniya A J Nepal Health Res Counc; 2021 Dec; 19(3):460-466. PubMed ID: 35140415 [TBL] [Abstract][Full Text] [Related]
52. Treatment of acute respiratory distress syndrome from COVID-19 with extracorporeal membrane oxygenation in obstetrical patients. Shih E; DiMaio JM; Squiers JJ; Krueger AR; Schwartz GS; Herd J; Bleich AT Am J Obstet Gynecol MFM; 2022 Mar; 4(2):100537. PubMed ID: 34813975 [TBL] [Abstract][Full Text] [Related]
53. SARS-CoV-2: Pathogenic Mechanisms and Host Immune Response. Yasmin H; Saha S; Butt MT; Modi RK; George AJT; Kishore U Adv Exp Med Biol; 2021; 1313():99-134. PubMed ID: 34661893 [TBL] [Abstract][Full Text] [Related]
54. Effectiveness of prone position in acute respiratory distress syndrome and moderating factors of obesity class and treatment durations for COVID-19 patients: A meta-analysis. Ashra F; Chen R; Kang XL; Chiang KJ; Pien LC; Jen HJ; Liu D; Hsiao SS; Chou KR Intensive Crit Care Nurs; 2022 Oct; 72():103257. PubMed ID: 35672215 [TBL] [Abstract][Full Text] [Related]
55. IL-17A and TNF-α as potential biomarkers for acute respiratory distress syndrome and mortality in patients with obesity and COVID-19. Leija-Martínez JJ; Huang F; Del-Río-Navarro BE; Sanchéz-Muñoz F; Muñoz-Hernández O; Giacoman-Martínez A; Hall-Mondragon MS; Espinosa-Velazquez D Med Hypotheses; 2020 Nov; 144():109935. PubMed ID: 32795834 [TBL] [Abstract][Full Text] [Related]
56. Immune-Based Therapy for COVID-19. Esmaeilzadeh A; Jafari D; Tahmasebi S; Elahi R; Khosh E Adv Exp Med Biol; 2021; 1318():449-468. PubMed ID: 33973194 [TBL] [Abstract][Full Text] [Related]
57. [Therapy of coronavirus disease 2019 induced acute respiratory distress syndrome is different from traditional acute respiratory distress syndrome]. Pan C; Xie JF; Qiu HB; Yang Y Zhonghua Shao Shang Za Zhi; 2020 May; 36(5):330-333. PubMed ID: 32456368 [TBL] [Abstract][Full Text] [Related]
58. Therapeutic mechanisms of mesenchymal stem cells in acute respiratory distress syndrome reveal potentials for Covid-19 treatment. Wang W; Lei W; Jiang L; Gao S; Hu S; Zhao ZG; Niu CY; Zhao ZA J Transl Med; 2021 May; 19(1):198. PubMed ID: 33971907 [TBL] [Abstract][Full Text] [Related]
59. COVID-19-associated acute respiratory distress syndrome versus classical acute respiratory distress syndrome (a narrative review). Krynytska I; Marushchak M; Birchenko I; Dovgalyuk A; Tokarskyy O Iran J Microbiol; 2021 Dec; 13(6):737-747. PubMed ID: 35222850 [TBL] [Abstract][Full Text] [Related]
60. Assessment of Interleukin-13(rs20541) Genomic Polymorphism in Patients with Acute Respiratory Distress Syndrome in Relation to COVID19 Infection. Modher Nabat Al-Ajrash A; Mohammed Ali SH; Al-Bayaa YJ; MohammedAl-Alwany SH; Al-Hijazi AY Arch Razi Inst; 2022 Dec; 77(6):2291-2298. PubMed ID: 37274898 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]